Cytokinetics price target raised to $65 from $59 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Cytokinetics to $65 from $59 and keeps an Overweight rating on the shares. Cytokinetics recently presented baseline characteristics of patients from the Phase 3 SEQUOIA-HCM study of aficamten at the HCM Society Scientific Sessions, revealing significant functional impairments despite receiving prior treatments, notably having reduced exercise capacity, highlighting a substantial unmet medical need in obstructive hypertrophic cardiomyopathy, the analyst tells investors in a research note.